抗酸剂对肠溶颗粒剂型奥美拉唑血浆浓度无影响。
Lack of effect of antacids on plasma concentrations of omeprazole given as enteric-coated granules.
作者信息
Tuynman H A, Festen H P, Röhss K, Meuwissen S G
机构信息
Department of Gastroenterology, Free University Hospital, Amsterdam, The Netherlands.
出版信息
Br J Clin Pharmacol. 1987 Dec;24(6):833-5. doi: 10.1111/j.1365-2125.1987.tb03256.x.
Abstract
Twelve male volunteers were studied after a single oral dose of 20 mg omeprazole given as enteric-coated granules with and without concomitant administration of 10 ml of a potent liquid antacid (buffering capacity 56.6 mmol 10 ml-1) under fasting conditions. No statistically significant differences were detected in median Cmax (0.41 approximately equal to 0.53 mumol l-1), the geometric mean AUC (0.80 approximately equal to 0.81 mumol l-1 h) or median tmax (1.25 h), with and without antacid.
摘要
12名男性志愿者在禁食条件下，单次口服20毫克肠溶颗粒剂型的奥美拉唑，同时给予或不给予10毫升强效液体抗酸剂（缓冲能力为56.6毫摩尔/10毫升）后接受研究。在有或没有抗酸剂的情况下，测得的Cmax中位数（0.41约等于0.53微摩尔/升）、几何平均AUC（0.80约等于0.81微摩尔/升·小时）或tmax中位数（1.25小时）均无统计学显著差异。
相似文献
1
Lack of effect of antacids on plasma concentrations of omeprazole given as enteric-coated granules.抗酸剂对肠溶颗粒剂型奥美拉唑血浆浓度无影响。
Br J Clin Pharmacol. 1987 Dec;24(6):833-5. doi: 10.1111/j.1365-2125.1987.tb03256.x.
2
[Decreased plasma levels of omeprazole after coadministration with magnesium-aluminium hydroxide dry suspension granules].[与氢氧化镁铝干混悬剂颗粒合用时奥美拉唑血浆水平降低]
Yakugaku Zasshi. 1999 Mar;119(3):221-8. doi: 10.1248/yakushi1947.119.3_221.
3
Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib.奥美拉唑或氢氧化铝/氢氧化镁抗酸剂对鲁米昔布药代动力学无影响。
Clin Pharmacokinet. 2004;43(5):341-8. doi: 10.2165/00003088-200443050-00006.
4
Antacids have no influence on the pharmacokinetics of rabeprazole, a new proton pump inhibitor, in healthy volunteers.抗酸剂对新型质子泵抑制剂雷贝拉唑在健康志愿者体内的药代动力学没有影响。
Int J Clin Pharmacol Ther. 1999 May;37(5):249-53.
5
Effective gastric acid suppression after oral administration of enteric-coated omeprazole granules.口服肠溶包衣奥美拉唑颗粒后有效的胃酸抑制作用。
Dig Dis Sci. 1997 Apr;42(4):715-9. doi: 10.1023/a:1018839425118.
6
Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers.对健康志愿者口服400毫克剂量莫西沙星后，抗酸剂和H2拮抗剂对其吸收影响的评估。
Clin Pharmacokinet. 2001;40 Suppl 1:39-48. doi: 10.2165/00003088-200140001-00006.
7
The effect of food and antacids on lansoprazole absorption and disposition.
Eur J Drug Metab Pharmacokinet. 1991;Spec No 3:315-20.
8
Clopidogrel bioavailability: absence of influence of food or antacids.氯吡格雷的生物利用度：食物或抗酸剂无影响。
Semin Thromb Hemost. 1999;25 Suppl 2:47-50.
9
Pharmacokinetics of oral omeprazole in llamas.口服奥美拉唑在美洲驼中的药代动力学。
J Vet Pharmacol Ther. 2005 Dec;28(6):539-43. doi: 10.1111/j.1365-2885.2005.00696.x.
10
Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.随机试验中口服溶液与普通片的双氯芬酸钾的药代动力学差异：进食与禁食状态的影响。
Headache. 2015 Feb;55(2):265-75. doi: 10.1111/head.12483. Epub 2014 Dec 24.
引用本文的文献
1
Pharmacokinetic drug interactions with anti-ulcer drugs.抗溃疡药物的药代动力学药物相互作用。
Clin Pharmacokinet. 1998 Aug;35(2):135-50. doi: 10.2165/00003088-199835020-00003.
2
Drug interactions with proton pump inhibitors.质子泵抑制剂的药物相互作用。
Drug Saf. 1997 Mar;16(3):171-9. doi: 10.2165/00002018-199716030-00003.
3
Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.酸泵抑制剂的药代动力学、代谢及相互作用。重点关注奥美拉唑、兰索拉唑和泮托拉唑。
Clin Pharmacokinet. 1996 Jul;31(1):9-28. doi: 10.2165/00003088-199631010-00002.
4
The effect of antacids and metoclopramide on omeprazole absorption and disposition.抗酸剂和甲氧氯普胺对奥美拉唑吸收与处置的影响。
Br J Clin Pharmacol. 1988 Jun;25(6):779-81. doi: 10.1111/j.1365-2125.1988.tb05271.x.
5
Influence of acid secretory status on absorption of omeprazole from enteric coated granules.胃酸分泌状态对奥美拉唑肠溶颗粒吸收的影响。
Br J Clin Pharmacol. 1991 Mar;31(3):275-8. doi: 10.1111/j.1365-2125.1991.tb05530.x.
6
Oral bioavailability of omeprazole before and after chronic therapy in patients with duodenal ulcer.十二指肠溃疡患者长期治疗前后奥美拉唑的口服生物利用度。
Br J Clin Pharmacol. 1991 Feb;31(2):166-70. doi: 10.1111/j.1365-2125.1991.tb05506.x.
7
Clinical pharmacology of omeprazole.奥美拉唑的临床药理学
Clin Pharmacokinet. 1991 Jan;20(1):38-49. doi: 10.2165/00003088-199120010-00003.
8
Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders.奥美拉唑。其药理学及在酸相关性疾病治疗应用的最新综述。
Drugs. 1991 Jul;42(1):138-70. doi: 10.2165/00003495-199142010-00008.
本文引用的文献
1
Effect of omeprazole--a gastric proton pump inhibitor--on pentagastrin stimulated acid secretion in man.奥美拉唑（一种胃质子泵抑制剂）对人五肽胃泌素刺激的胃酸分泌的影响。
Gut. 1983 Apr;24(4):270-6. doi: 10.1136/gut.24.4.270.
2
Determination of omeprazole and metabolites in plasma and urine by liquid chromatography.采用液相色谱法测定血浆和尿液中的奥美拉唑及其代谢物。
J Chromatogr. 1984 Aug 10;309(2):347-56. doi: 10.1016/0378-4347(84)80042-0.
3
Oral pharmacokinetics of omeprazole.奥美拉唑的口服药代动力学。
Eur J Clin Pharmacol. 1984;26(5):641-3. doi: 10.1007/BF00543502.
4
Effects of single and repeated doses of omeprazole on gastric acid and pepsin secretion in man.单次及重复剂量奥美拉唑对人体胃酸和胃蛋白酶分泌的影响。
Gut. 1984 Jul;25(7):707-10. doi: 10.1136/gut.25.7.707.
5
Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+)ATPase.取代苯并咪唑通过阻断（H⁺+K⁺）ATP酶来抑制胃酸分泌。
Nature. 1981 Mar 12;290(5802):159-61. doi: 10.1038/290159a0.
6
Omeprazole: a study of its inhibition of gastric pH and oral pharmacokinetics after morning or evening dosage.奥美拉唑：早晨或晚上给药后对胃内pH值的抑制作用及口服药代动力学研究。
Gastroenterology. 1985 Jan;88(1 Pt 1):64-9. doi: 10.1016/s0016-5085(85)80133-5.
7
Development of an oral formulation of omeprazole.奥美拉唑口服制剂的研发。
Scand J Gastroenterol Suppl. 1985;108:113-20. doi: 10.3109/00365528509095824.
Zotero 插件